Insights

Strategic Partnerships EuMederis is actively seeking investors and commercialization partners to advance preclinical candidates in osteoporosis, pain, and asthma into clinical trials, presenting immediate BD outreach opportunities with biotech investors, CROs, and pharma alliances.

Clinical候 Candidate Advantage Proprietary EuPort modification enhances bioavailability and duration of action for peptide therapeutics, offering a differentiating value proposition to potential licensees or co-development partners focusing on long-acting peptide drugs.

Diversified Pipeline Signals Lead candidates Eu-232 and Eu-178 demonstrate potent profiles in osteoporosis and analgesia peripherally, suggesting collaboration focus areas in endocrinology, pain management, and inflammatory respiratory conditions.

Funding Readiness Current revenue tier indicates early-stage traction; target conversations with strategic investors and grant programs could accelerate preclinical to clinical progression and de-risk partnerships.

Tech & Infrastructure Cloud and web-enabled operations (AWS, Azure, WordPress) imply scalable product development and potential for digital collaboration platforms with partners, CROs, and contract manufacturing organizations.

Similar companies to EuMederis Pharmaceuticals, Inc.

EuMederis Pharmaceuticals, Inc. Tech Stack

EuMederis Pharmaceuticals, Inc. uses 8 technology products and services including Amazon Web Services, WordPress, oEmbed, and more. Explore EuMederis Pharmaceuticals, Inc.'s tech stack below.

  • Cloud Hosting
  • Content Management System
  • oEmbed
    Dev Tools
  • Yahoo Mail for business
    Email Hosting
  • Google Fonts API
    Font Scripts
  • Platform As A Service
  • Material Design Lite
    UI Frameworks
  • HTTP/3
    Web & Portal Technology

EuMederis Pharmaceuticals, Inc.'s Email Address Formats

EuMederis Pharmaceuticals, Inc. uses at least 0 email formats:
EuMederis Pharmaceuticals, Inc. Email FormatsExamplePercentage

Frequently Asked Questions

What is EuMederis Pharmaceuticals, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact EuMederis Pharmaceuticals, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is EuMederis Pharmaceuticals, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
EuMederis Pharmaceuticals, Inc.'s official website is eumederis.com and has social profiles on LinkedIn.

How much revenue does EuMederis Pharmaceuticals, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, EuMederis Pharmaceuticals, Inc.'s annual revenue is estimated to be $1M - $10M.

What is EuMederis Pharmaceuticals, Inc.'s NAICS code?

Minus sign iconPlus sign icon
EuMederis Pharmaceuticals, Inc.'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does EuMederis Pharmaceuticals, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, EuMederis Pharmaceuticals, Inc. has approximately 1 employees across 1 continents, including North America. Key team members include Founding Chief Executive Officer And Chief Strategy Officer: J. W. Explore EuMederis Pharmaceuticals, Inc.'s employee directory with LeadIQ.

What industry does EuMederis Pharmaceuticals, Inc. belong to?

Minus sign iconPlus sign icon
EuMederis Pharmaceuticals, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does EuMederis Pharmaceuticals, Inc. use?

Minus sign iconPlus sign icon
EuMederis Pharmaceuticals, Inc.'s tech stack includes Amazon Web Services, WordPress, oEmbed, Yahoo Mail for business, Google Fonts API, Microsoft Azure, Material Design Lite and HTTP/3.

When was EuMederis Pharmaceuticals, Inc. founded?

Minus sign iconPlus sign icon
EuMederis Pharmaceuticals, Inc. was founded in 2009.
EuMederis Pharmaceuticals, Inc. logo

EuMederis Pharmaceuticals, Inc.

Pharmaceutical ManufacturingTexas, United States0-1 Employees

EuMederis Pharmaceuticals, Inc. is a pharmaceutical manufacturer focused on the design and development of peptide-based therapeutics enhanced for bioavailability and duration of action through its proprietary EuPort modification. The company aims to identify and advance best-in-class clinical candidates by applying this modification to peptide molecules, creating new chemical entities with improved pharmaceutical properties. Early work includes applications in osteoporosis and opioid-related analgesia, illustrating a pursuit of preclinical candidates across osteoporosis, pain, and asthma. Based in Sugar Land, Texas, EuMederis operates with a small team and seeks partnerships to bring its preclinical programs into clinical trials. The company positions itself within the peptide therapeutics niche of the broader pharmaceutical industry, aiming to partner with investors and commercialization partners to advance its pipeline.

Section iconCompany Overview

Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2009
Employees
0-1

Section iconFunding & Financials

  • $1M - $10M

    EuMederis Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.